Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Study Objective: This study investigated the 1-year risk of injuries and poisonings among anabolic androgenic steroid users compared with controls from the general population.
Methods: In a cohort study conducted in Denmark, 1,189 anabolic androgenic steroid users were identified through a national antidoping program and matched with 59,450 controls. Participants were followed for 1 year. Data on hospital contacts, educational length, and occupational status were retrieved from nationwide registries. The primary outcomes were the incidence of injuries and poisonings. The secondary outcomes differentiated between fracture and nonfracture injuries, and medicinal versus nonmedicinal causes of poisonings, and described specific causes of injury-related hospital contacts.
Results: Anabolic androgenic steroid users had significantly higher incidences of injuries and poisonings compared with controls. The risk difference for any injury was 7.8% (95% confidence interval [CI] 5.5 to 10.2) and the adjusted hazard ratio (aHR) was 1.46 (95% CI 1.29 to 1.66). Specifically, the risk of fractures was more than doubled among anabolic androgenic steroid users (aHR of 2.23, 95% CI 1.72 to 2.89), with head injuries being particularly prevalent. The risk difference for any poisoning was 1.2% (95% CI 0.5 to 1.9) and the aHR was 2.98 (95% CI 1.82 to 4.90). Medicinal poisoning was the most common poisoning among anabolic androgenic steroid users, with an aHR of 3.53 (95% CI 1.94 to 6.41).
Conclusion: Anabolic androgenic steroid use is associated with an increased risk of both injuries and poisonings, thereby quantifying a substantial risk of external harm among users.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.annemergmed.2025.02.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Long-term oral glucocorticoid use is associated with complications, healthcare resource utilization, and costs among patients with dermatomyositis or polymyositis.
Clin Rheumatol
September 2025
Immunology Market Access, Johnson & Johnson, Horsham, PA, USA.
Introduction/objective: Oral glucocorticoids (OGC) are conventionally used as first-line treatment for dermatomyositis (DM) and polymyositis (PM). This study evaluated clinical and economic outcomes associated with long-term (LT) OGC use in DM/PM.
Methods: Adults with ≥ 2 medical claims of DM/PM 30‒365 days apart from January 1, 2016, to December 31, 2022, and ≥ 1 diagnosis code of a physician specialty of interest were selected from the MarketScan Commercial and Medicare Supplemental databases.
Detection of Anabolic Androgenic Steroids and Steroid Esters-Comparing Dried Blood Spots Collection Devices and Urine Samples.
Drug Test Anal
September 2025
Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden.
Dried blood spots (DBS) have emerged as a promising complement, and in some settings, an alternative, to urine for anabolic androgenic steroid (AAS) testing, offering advantages such as minimal invasiveness, simplified storage, and transportation. This study evaluated two DBS collection devices-cellulose-based Capitainer-B50 and polymer-based Tasso-M20-and compared results with traditional urine analysis. Ten self-reported AAS users were recruited and provided matched urine and DBS samples.
View Article and Find Full Text PDFFactors Influencing Cyclosporine Trough and Two-Hour Post-dose Concentrations in Children with Idiopathic Nephrotic Syndrome.
Indian Pediatr
September 2025
Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India.
Objective: To determine the cyclosporine trough (C) and two-hour post-dose concentrations (C) in children with nephrotic syndrome (NS) and study the factors influencing them.
Methods: In this ambispective cohort study, children with NS (including frequently relapsing, steroid-dependent and steroid-resistant nephrotic syndrome) on cyclosporine therapy were enrolled. Clinical and laboratory data were recorded.
Effect of spironolactone on cardiovascular and renal outcomes in patients with chronic kidney disease.
Clin Kidney J
September 2025
Division of Nephrology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
Background: Steroidal mineralocorticoid receptor antagonists (MRAs), including spironolactone, effectively treat resistant hypertension, reduce proteinuria and lower mortality in heart failure with reduced ejection fraction. However, their long-term effects in chronic kidney disease (CKD) remain unclear. This study investigated spironolactone's impact on end-stage renal disease (ESRD), major adverse cardiovascular events (MACE), hyperkalemia and mortality in CKD patients.
View Article and Find Full Text PDFQuality of care in inflammatory bowel disease from patient's perspective using QUOTE-IBD: a Greek multicenter prospective study.
Eur J Gastroenterol Hepatol
July 2025
Department of Gastroenterology, University Hospital of Heraklion, Greece.
Objective: Most of the existing instruments assessing quality of care (QoC) are based on the perception of healthcare providers that may differ from that of healthcare users. We aimed to measure QoC through the patient's eyes in a Greek cohort of patients with inflammatory bowel disease (GR QUOTE-IBD) and to investigate putative sociodemographic and disease-related QoC predictors.
Methods: GR QUOTE-IBD questionnaire was delivered to patients at their regular follow-up visit, and adequate time was offered to fill it in.